These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 23747187)

  • 1. An unusual presentation of a chronic lymphocytic leukemia patient with 17p deletion after reduced-intensity transplantation: Richter syndrome and concomitant graft-versus-host disease--case report.
    Salihoglu A; Ozbalak M; Keskin D; Tecimer T; Soysal T; Ferhanoglu B
    Transplant Proc; 2013 Sep; 45(7):2845-8. PubMed ID: 23747187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.
    Schetelig J; van Biezen A; Brand R; Caballero D; Martino R; Itala M; García-Marco JA; Volin L; Schmitz N; Schwerdtfeger R; Ganser A; Onida F; Mohr B; Stilgenbauer S; Bornhäuser M; de Witte T; Dreger P
    J Clin Oncol; 2008 Nov; 26(31):5094-100. PubMed ID: 18711173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia.
    Richardson SE; Khan I; Rawstron A; Sudak J; Edwards N; Verfuerth S; Fielding AK; Goldstone A; Kottaridis P; Morris E; Benjamin R; Peggs KS; Thomson KJ; Vandenberghe E; Mackinnon S; Chakraverty R
    Br J Haematol; 2013 Mar; 160(5):640-8. PubMed ID: 23293871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
    Dreger P; Brand R; Hansz J; Milligan D; Corradini P; Finke J; Deliliers GL; Martino R; Russell N; Van Biezen A; Michallet M; Niederwieser D;
    Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of allogeneic stem cell transplantation on high risk chronic lymphocytic leukaemia: a single centre retrospective analysis.
    Válková V; Schwarz J; Vítek A; Marková M; Pohlreich D; Benešová K; Michalová K; Cetkovský P; Trněný M
    Hematol Oncol; 2011 Mar; 29(1):22-30. PubMed ID: 20535783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
    Caballero D; García-Marco JA; Martino R; Mateos V; Ribera JM; Sarrá J; León A; Sanz G; de la Serna J; Cabrera R; González M; Sierra J; San Miguel J
    Clin Cancer Res; 2005 Nov; 11(21):7757-63. PubMed ID: 16278397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding and managing ultra high-risk chronic lymphocytic leukemia.
    Stilgenbauer S; Zenz T
    Hematology Am Soc Hematol Educ Program; 2010; 2010():481-8. PubMed ID: 21239840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
    Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis.
    Poon ML; Fox PS; Samuels BI; O'Brien S; Jabbour E; Hsu Y; Gulbis A; Korbling M; Champlin R; Abruzzo LV; Bassett RL; Khouri IF
    Leuk Lymphoma; 2015 Mar; 56(3):711-5. PubMed ID: 24913509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia (CLL) patients with the aberration of p53 gene].
    Wang L; Miao K; Fan L; Xu J; Wu H; Li J; Xu W
    Zhonghua Xue Ye Xue Za Zhi; 2016 Apr; 37(4):308-12. PubMed ID: 27093994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
    Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W;
    J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial.
    Ritgen M; Böttcher S; Stilgenbauer S; Bunjes D; Schubert J; Cohen S; Humpe A; Hallek M; Kneba M; Schmitz N; Döhner H; Dreger P;
    Leukemia; 2008 Jul; 22(7):1377-86. PubMed ID: 18418404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High incidence of chronic graft-versus-host disease after myeloablative allogeneic stem cell transplantation for chronic lymphocytic leukemia in Sweden: graft-versus-leukemia effect protects against relapse.
    Machaczka M; Johansson JE; Remberger M; Hallböök H; Lazarevic VLj; Wahlin BE; Omar H; Wahlin A; Juliusson G; Kimby E; Hägglund H
    Med Oncol; 2013 Dec; 30(4):762. PubMed ID: 24214180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approach.
    Schnaiter A; Stilgenbauer S
    Hematol Oncol Clin North Am; 2013 Apr; 27(2):289-301. PubMed ID: 23561474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results.
    Delgado J; Espinet B; Oliveira AC; Abrisqueta P; de la Serna J; Collado R; Loscertales J; Lopez M; Hernandez-Rivas JA; Ferra C; Ramirez A; Roncero JM; Lopez C; Aventin A; Puiggros A; Abella E; Carbonell F; Costa D; Carrio A; Gonzalez M; ;
    Br J Haematol; 2012 Apr; 157(1):67-74. PubMed ID: 22224845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
    Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
    Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
    Delgado J; Pillai S; Benjamin R; Caballero D; Martino R; Nathwani A; Lovell R; Thomson K; Perez-Simon JA; Sureda A; Kottaridis P; Vazquez L; Peggs K; Sierra J; Milligan D; Mackinnon S
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1288-97. PubMed ID: 18940684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?
    Tam CS; Stilgenbauer S
    Leuk Lymphoma; 2015 Mar; 56(3):587-93. PubMed ID: 25641428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Richter syndrome: clinical characteristics and treatment experiences].
    Li ZJ; Xu Y; Zhang PH; Liu W; Yi SH; Zou DH; Qi JY; Zhao YZ; Qiu LG
    Zhonghua Yi Xue Za Zhi; 2012 Dec; 92(46):3254-6. PubMed ID: 23328508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.